Stocks · News reference
Jefferies analyst Akash Tewari initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy rating and announces Price Target of $50.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Damora Therapeutics granted equity awards to five newly-hired non-executive employees on October 1, 2026, consisting of options to purchase 144,400 ordinary shares at $21.28 per share with a 10-year term. The inducement grants were approved by the Compensation Committee as material incentives for employment acceptance.
Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $40 price target.
Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 85 percent increase over losses of $(2.60) per share from